drugset / Trial / NCT05118360
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a phase 2, randomized, double-blind, placebo controlled study in adults with biopsy confirmed NASH. The study is aimed at evaluating efficacy and tolerability of ASC41 in adults with NASH.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2024-11-10
- Completion
- 2025-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASC41 | Unknown | 2 mg | Oral |
| Subject | ASC41 | Unknown | 4 mg | Oral |